Dengue Fever (DF) is a mosquito-borne disease (Aedes) caused by single-stranded RNA viruses of the family flaviviridae. DF has a wide spectrum of symptoms ranging from a mild febrile illness to severe outcomes such as hospitalization and death as observed in dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). Published estimates indicate that 390m dengue infections occur each year of which 20-30% are symptomatic (any severity) and 17-49K deaths occur. It is estimated that 3.9bn of the global population (~90 countries) are thought to be at risk from dengue infection, mainly urban dwellers in tropical and sub-tropical countries. Importantly, most of the estimated deaths per year are in children (< 15yrs). No specific treatment is available.
Dengue cases are at a record high in 2024 with ~12.4m probable cases reported (as of 16th September 2024) and ~7.8K deaths. Brazil is particularly affected prompting the health authorities to begin mass vaccination campaigns with Takeda Vaccines Qdenga (TAK-003) in priority age groups in certain high-transmission municipalities. Qdenga which is undergoing global registrations is expected to face competition in the PAHO region from Instituto Butantans single-dose vaccine (Butantan-DV, NIAID-licensed) which has also met its endpoint in a large Phase 3 study. Other dengue vaccines such as Merck & Co, V181, Panacea Biotech, DengiALL and KM Biologics/Meiji, KD-382 + others are in development.
This MarketVIEW product consists of a detailed Executive presentation (>375 slides) and a comprehensive MS-Excel forecast model (250 worksheets) which forecast the potential commercial value of dengue endemic vaccine(s) by competitor across 55 endemic markets to 2036. The model(s) contain value ($ m) and volume (mio doses) predictions (public and private sector) in adjustable age segments e.g., >4 yrs, >19 yrs. LO, BASE and HI forecast scenarios include potential demand from selected country mass campaigns, routine inclusion and expected approvals from 2022 onwards. An intra-state or region roll-out analysis is also included for Brazil and The Philippines. New case studies to guide forecast uptake projections are included for 2024.
THIS PRODUCT IS AN EXECUTIVE PRESENTATION (.pdf >375 slides + MS-Excel forecast MODELS/Worksheets #with most recent market events
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. Global is all 3 regions
For UK orders VAT will be added at 20%. Licenses are non-exclusive and non-transferable to 3rd parties. Discounted versions have exclusions.
Please review the TERMS and CONDITIONS of purchase.
